175 related articles for article (PubMed ID: 15561985)
1. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ
Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
3. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
Etzioni R; Gulati R; Falcon S; Penson DF
Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Brenner H; Arndt V
J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
[TBL] [Abstract][Full Text] [Related]
5. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
Telesca D; Etzioni R; Gulati R
Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
Colli JL; Amling CL
Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
[TBL] [Abstract][Full Text] [Related]
8. Impact of screening on prostate cancer rates and trends.
Mettlin C
Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
10. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
11. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
[TBL] [Abstract][Full Text] [Related]
12. Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
Albertsen PC
Acta Oncol; 2005; 44(3):255-64. PubMed ID: 16076698
[TBL] [Abstract][Full Text] [Related]
13. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
Merrill RM; Stephenson RA
J Urol; 2000 Feb; 163(2):503-10. PubMed ID: 10647666
[TBL] [Abstract][Full Text] [Related]
14. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
[TBL] [Abstract][Full Text] [Related]
15. PSA screening and prostate cancer mortality.
Perron L; Moore L; Bairati I; Bernard PM; Meyer F
CMAJ; 2002 Mar; 166(5):586-91. PubMed ID: 11898936
[TBL] [Abstract][Full Text] [Related]
16. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States.
Jemal A; Ward E; Wu X; Martin HJ; McLaughlin CC; Thun MJ
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):590-5. PubMed ID: 15767335
[TBL] [Abstract][Full Text] [Related]
17. PSA testing in Austria: induced morbidity and saved mortality.
Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
[TBL] [Abstract][Full Text] [Related]
18. Rural residence and prostate cancer screening with prostate-specific antigen.
Stamatiou K; Skolarikos A
Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
[TBL] [Abstract][Full Text] [Related]
19. Comparison of prostate-specific antigen and hormone levels among men in Singapore and the United States.
Cheng I; Yu MC; Koh WP; Pike MC; Kolonel LN; Henderson BE; Stram DO
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1692-6. PubMed ID: 16030103
[TBL] [Abstract][Full Text] [Related]
20. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
